Amyotrophic Lateral Sclerosis

Treatment with tofersen in patients with superoxide 1 dismutase 1 ALS was linked to preservation of motor function, maintenance of muscle strength and reduction of disease-specific biomarkers, data show.

Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.

For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved staggered regimen of the drug plus placebo, according to a poster presented at AANEM.

A Georgia-based biotechnology company has secured a U.S. patent for an exosome-based therapy to treat neuroinflammation that occurs in a range of neurodegenerative disease, according to the manufacturer.

Neurotechnology company Synchron announced the first use of Apple Vision Pro with a patient implanted with its brain-computer interface, which allows users to make commands without using their hands or voice.

PHILADELPHIA — In this interview, Michael Fisher, MD, highlights a keynote address presented by Leigh Hochberg, MD, PhD, from the International Symposium on Pediatric Neuro-Oncology.

NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.

The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat those with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene.

The FDA has cleared an investigational new drug application for a phase 1/2 clinical trial to examine a novel, once-daily pill for the treatment of individuals with amyotrophic lateral sclerosis, according to the manufacturer.

The Foundation for the NIH has announced the launch of a public-private partnership to advance knowledge of and accelerate drug development for individuals affected by amyotrophic lateral sclerosis.